Three years ago I was diagnosed with mgus and the oncologist wanted to start me on drugs right away, I was hesitant to say the least since my wife dies a few years before from Pancreatic cancer and I saw first hand what the drugs can do to you.
So I decided to get a second opinion from a specialist over in Portland Oregon. Best decision I ever made, it became obvious that he miss read the test results from the scans.
Three years later I now have Active Myeloma based on Light chain increases which are now 129.85 instead of 1.65 and the Immunoglobulin G is low at 440 and the A i a little high 478. The free kappa light chains is 441.5 and the lambda is 3.4.
Now they want to start treatment after I have another Pet scam. They are recommending I start with daratumumab and dexamethasone and if I do well than add lenalidomide. Has anyone had this type of experience with these drugs?

Your Feed
Filter by
See content from
HealthTree Foundation Pillar Three: A Powerful Patient Data Portal
Posted by
HealthTree

Read article
HealthTree Foundation Pillar Three: A Powerful Patient Data Portal
Posted by
HealthTree

Read article
HealthTree Foundation Pillar Three: A Powerful Patient Data Portal
Posted by
HealthTree

Read article
HealthTree Foundation Pillar Three: A Powerful Patient Data Portal
Posted by
HealthTree

Read article
Playlist: IMS 2023
Charting the Genetic Evolution of Myeloma Cells | Faith Davies, MD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Managing Renal Failure | Efstathious Kastritis, MD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Individualizing Frontline Treatment to Get the Best Outcomes | Xavier Leleu, MD, PhD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Key Take Aways from IMS 2023 | Rafael Fonseca, MD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Impact of Racial Disparities in Myeloma | Doctors Cole and Kumar | IMS 2023
Video details & playlist
Playlist: IMS 2023
Update from IMS on Novel Technologies in Multiple Myeloma | Gareth Morgan, MD, PhD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Monoclonal Gammopathy of Unknown Significance | Urvi Shah, MD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Using a Single Cell Approach to Define Mechanisms of Progression | Irene Ghobrial, MD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Serial MRD Assessments as a Surrogate for Long Term PFS | Frits van Rhee, MD | IMS 2023
Video details & playlist
Playlist: IMS 2023
Sustained MRD Negativity in Transplant Eligible Patients | Camila Guerrero, PhD | IMS 2023
Video details & playlist
HealthTree Foundation Pillar Three: A Powerful Patient Data Portal
Posted by
HealthTree

Read article


